Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

BACKGROUND: Abemaciclib was recently approved by the European Medicines Agency in combination with adjuvant endocrine therapy (ET) for adult patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−), node-positive early breast cancer (EBC) at high risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Davie, Alison, Traoré, Sory, Giovannitti, Massimo, Pompilio, Giuseppe, Lambton, Mark, Cakar, Esra, Chatterjee, Anuja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551672/
https://www.ncbi.nlm.nih.gov/pubmed/37811343
http://dx.doi.org/10.33393/grhta.2023.2561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551672/
https://www.ncbi.nlm.nih.gov/pubmed/37811343
http://dx.doi.org/10.33393/grhta.2023.2561

Ejemplares similares